宏基因组下一代测序用于病原体检测的现状及展望

Current situation and prospect of next generation sequencing of macrogenome for pathogen detection

所有的病原体都含有DNA或RNA基因组,这使得基因测序成为一独特的病原体检测方法。自2004年以来,高通量测序(也称作下一代测序next generation sequencing,NGS)的成本已经降低了几个数量级,而且它已经发展成为一个能够检测患者临床样本中的微生物,并对其进行分类的技术平台。本文综述了非靶向宏基因组测序技术在感染性疾病临床诊断中的应用,特别是在传统诊断方法有局限性的领域。综述内容包括下一代测序在病原体检测的优势、宏基因测序的临床应用、宏基因检测的局限性及可能的解决方案。

All pathogens contain DNA or RNA genomes,making gene sequencing a unique way to detect pathogens.High-throughput sequencing(also known as next generation sequencing,NGS)has become cheaper by orders of magnitude since 2004,and it has developed into a technology platform for detecting and classifying microbes in clinical samples of patients.This paper reviews the application of non-targeted macrogenome sequencing in clinical diagnosis of infectious diseases,especially in the field where traditional diagnostic methods have limitations.The review includes the advantages of next-generation sequencing in pathogen detection,the clinical application of macrogenome sequencing,the limitations of macrogenome sequencing,and possible solutions.